HEFEI LIFEON PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.46 CNY | -1.01% |
|
-7.27% | -16.66% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.52B 210M | Sales 2025 * | 1.82B 252M | Capitalization | 3.75B 518M |
|---|---|---|---|---|---|
| Net income 2024 * | 285M 39.41M | Net income 2025 * | 336M 46.46M | EV / Sales 2024 * | 2.47 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
11.1
x | Employees | 1,315 |
| Yield 2024 * |
2.28% | Yield 2025 * |
2.49% | Free-Float | 35.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.01% | ||
| 1 week | -7.27% | ||
| Current month | -0.72% | ||
| 1 month | +21.43% | ||
| 3 months | +8.91% | ||
| 6 months | -16.00% | ||
| Current year | -16.66% |
1 week
23.15
24.62
1 month
18.9725.98
Current year
16.4928.65
1 year
16.4944.66
3 years
16.4944.66
5 years
16.4344.66
10 years
16.4344.66
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Juan Deng
FOU | Founder | 60 | 02-07-15 |
Shao Bing Gou
DFI | Director of Finance/CFO | 48 | 10-07-31 |
Jun Chen
CTO | Chief Tech/Sci/R&D Officer | 62 | 05-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shi Hong Zhou
BRD | Director/Board Member | 61 | 17-11-14 |
Mo Rong Yang
BRD | Director/Board Member | 58 | 20-09-22 |
Jun Qiu Ji
FOU | Founder | 63 | 02-07-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 23.46 | -1.01% | 1,450,500 |
| 24-05-16 | 23.7 | -0.63% | 2,534,560 |
| 24-05-15 | 23.85 | -1.00% | 3,338,642 |
| 24-05-14 | 24.09 | -1.55% | 4,293,681 |
| 24-05-13 | 24.47 | -3.28% | 2,915,169 |
End-of-day quote Shenzhen S.E., May 16, 2024
More quotes
Hefei Lifeon Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical preparations and active pharmaceutical ingredients (APIs). The Company is also engaged in the wholesale and retailing of pharmaceuticals and medical devices. The Company's main products involve cardiovascular drugs, digestive system drugs and skin topical drugs.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
23.46
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.66% | 519M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.85% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 003020 Stock
